Subir Paul, MD
Nephrology · Florence, ALNPI 1922006816
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,720 of the $25,771 with a category attached, or 64.9%. 35 manufacturers reported payments, led by Vifor Pharma, Inc. at 42.9% of the total. Reporting peaked in 2019 at $10,915 and has fallen 91.5% since, to $929 in 2025. Among nephrology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $78.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$11K
- AstraZeneca$6K
- OPKO Pharmaceuticals, LLC$4K
- Akebia Therapeutics Inc$2K
- Novartis$404
- Amgen$384
- plus $2K from 29 others
Across 7 payments — averaging $4401.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$15K
- OPKO Pharmaceuticals, LLC$12K
- AstraZeneca$4K
What the payments were for
- Speaking & faculty fees$16,72065%
- Travel & lodging$2,79611%
- Food & beverage$5,89623%
- Education$3581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 50 | $11,062 |
| AstraZeneca(2 entities) | 30 | $5,759 |
| OPKO Pharmaceuticals, LLC | 90 | $3,576 |
| Akebia Therapeutics Inc | 25 | $2,298 |
| Novartis | 16 | $404 |
| Amgen(2 entities) | 16 | $384 |
| Bayer | 12 | $329 |
| Otsuka America Pharmaceutical, Inc. | 10 | $209 |
| Calliditas Therapeutics US Inc. | 9 | $191 |
| Lilly USA, LLC | 8 | $154 |
| Boehringer Ingelheim | 7 | $148 |
| Aurinia Pharma U.S., Inc. | 5 | $140 |
| Mallinckrodt Enterprises LLC | 3 | $131 |
| Novo Nordisk | 8 | $129 |
| Fresenius USA Marketing, Inc. | 6 | $115 |
| Corcept Therapeutics | 4 | $89 |
| Gilead | 4 | $86 |
| Nuwellis, Inc. | 1 | $81 |
| Ardelyx, Inc. | 4 | $67 |
| Travere Therapeutics, Inc. | 2 | $44 |
| Bard Peripheral Vascular, Inc. | 1 | $42 |
| GSK | 2 | $38 |
| Mallinckrodt Hospital Products Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| AbbVie | 1 | $28 |
| Shield Therapeutics Inc | 1 | $27 |
| Vantive US Healthcare LLC | 1 | $25 |
| BETA Bionics, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Nxstage Medical, Inc. | 1 | $16 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,771 in reported general payments places this provider in the 90th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RayaldeeCalcifediol | 55 | $80,092 |
| FarxigaDapagliflozin Propanediol | 65 | $42,920 |
| OzempicSemaglutide | 24 | $26,930 |
| JardianceEmpagliflozin | 22 | $17,660 |
| MounjaroTirzepatide | 11 | $15,266 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $14,956 |
| KerendiaFinerenone | 12 | $7,599 |
| Sevelamer Carbonate | 34 | $4,418 |
| Calcium Acetate | 50 | $3,038 |
| Torsemide | 64 | $1,651 |
| Allopurinol | 139 | $1,532 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 20 | $1,125 |
| Cinacalcet Hcl | 23 | $983 |
| Losartan Potassium | 72 | $928 |
| Calcitriol | 23 | $849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| OPKO Pharmaceuticals, LLCRayaldee | $3,576 | $80,09255 claims |
| AstraZenecaFarxiga | $5,759 | $42,92065 claims |
| Novo NordiskOzempic | $129 | $26,93024 claims |
| Boehringer IngelheimJardiance | $148 | $17,66022 claims |
| Lilly USA, LLCMounjaro | $154 | $15,26611 claims |
| BayerKerendia | $329 | $7,59912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 164 nephrology providers in Alabama.
Other nephrology in Florence
- Narasimha BoorguFlorence$10K
- Dwight MatthewFlorence$4K
- Rajesh BoorguFlorence$4K
- Michael QuadriniHuntsville$323K
- Dana RizkBirmingham$196K
- Sumeet MunjalMontgomery$191K
- Eric WallaceBirmingham$172K
- Phillip MadoniaAlabaster$165K
- Thomas OzbirnHomewood$133K
- David WarnockBirmingham$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.